Adam Feuerstein

Tenax Therapeutics reported negative results Monday from a late-stage clinical trial evaluating an experimental treatment for a type of heart failure associated with high blood pressure in the lungs.

In biotech, companies aren't shy about sharing detailed results when they bolster their case Biotech companies don't hide or obfuscate strong data.

New therapy for Prader-Willi syndrome is linked to reports of deaths, severe side effects

A rare disease drug is once again forcing difficult decisions for patients and their caregivers

Zenbexus is also first drug cleared using more sensitive measure of cancer remission

Data could imperil biotech's plans to seek regulatory approval in competitive field

The study setback imperiled Eyepoint's plans to seek regulatory approval for the drug, Duravyu, and caused its stock price to plummet. Shares of Bedford-based Ocular Therapeutix, the maker of a competing eye treatment that will be submitted to the Food and Drug Administration later this year, rose in reaction.

Publicly, the company maintains confidence in its drug. It's not clear why This story first appeared in Adam's Biotech Scorecard, a subscriber-only newsletter.

It's not hyperbole when you consider a new treatment for pancreatic cancer and an mRNA neoantigen vaccine

The therapy, Rasonque from Revolution Medicines, nearly doubled overall survival in a clinical trial